Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Pharm Res ; 29(9): 2534-42, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22688900

ABSTRACT

PURPOSE: To characterize temporal exposure and elimination of 5 gold/dendrimer composite nanodevices (CNDs) (5 nm positive, negative, and neutral, 11 nm negative, 22 nm positive) in mice using a physiologically based mathematical model. METHODS: 400 ug of CNDs is injected intravenously to mice bearing melanoma cell lines. Gold content is determined from plasma and tissue samples using neutron activation analysis. A physiologically based pharmacokinetic (PBPK) model is developed for 5 nm positive, negative, and neutral and 11 nm negative nanoparticles and extrapolated to 22 nm positive particles. A global sensitivity analysis is performed for estimated model parameters. RESULTS: Negative and neutral particles exhibited similar distribution profiles. Unique model parameter estimates and distribution profiles explain similarities and differences relative to positive particles. The model also explains mechanisms of elimination by kidney and reticuloendothelial uptake in liver and spleen, which varies with particle size and charge. CONCLUSION: Since the PBPK model can capture the diverse temporal profiles of non-targeted nanoparticles, we propose that when specific binding ligands are lacking, size and charge of nanodevices govern most of their in vivo interactions.


Subject(s)
Models, Theoretical , Nanotechnology , Pharmacokinetics , Animals , Cell Line, Tumor , Mice , Particle Size
2.
J Biomed Inform ; 44(4): 655-62, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21310264

ABSTRACT

StarBRITE is a one-stop, web-based research portal designed to meet the day-to-day needs of the Vanderbilt University and Meharry Medical College research community during the planning and conduct of research studies. StarBRITE serves as the main online location for research support addressing issues such as identification and location of resources, identification of experts, guidance for regulatory applications and approvals, regulatory assistance, funding requests, research data planning and collection, and serves as a central repository for educational offerings. To date, there have been more than 590,038 StarBRITE hits by more than 6582 cumulative users. We present here StarBRITE design objectives, details about technical infrastructure and system components, status report and activity metrics for the first 2.75-years of operation, and a report of lessons learned during organizing, launching and refining the portal.


Subject(s)
Biomedical Research , Database Management Systems , Internet , Universities , Humans , Medical Informatics
3.
J Aerosol Med Pulm Drug Deliv ; 23(2): 77-89, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19778268

ABSTRACT

BACKGROUND: Many infectious diseases that cause significant morbidity and mortality, especially in the developing world, could be preventable through vaccination. The effort to produce safe, thermally stable, and needle-free mucosal vaccines has become increasingly important for global health considerations. We have previously demonstrated that a thermally stable nanoemulsion, a mucosal adjuvant for needle-free nasal immunization, is safe and induces protective immunity with a variety of antigens, including recombinant protein. The successful use of nanoemulsion-based vaccines, however, poses numerous challenges. Among the challenges is optimization of the formulation to maintain thermal stability and potency and another is accuracy and efficiency of dispensing the vaccines to the nasal mucosa in the anterior and turbinate region of the nasal cavity or potentially to the nasopharynx-associated lymphoid tissue. METHODS: We have examined the effects of different diluents [phosphate-buffered saline (PBS) and 0.9% NaCl] on the stability and potency of nanoemulsion-based vaccines. In addition, we have determined the efficiency of delivering them using commercially available nasal spray devices (Pfeiffer SAP-62602 multidose pump and the BD Hypak SCF 0.5 ml unit dose Accuspray(TM)). RESULTS: We report the stability and potency of PBS-diluted ovalbumin-nanomeulsion mixtures for up to 8 months and NaCl-diluted mixtures up to 6 months when stored at room temperature. Significant differences in spray characteristics including droplet size, spray angle, plume width, and ovality ratios were observed between the two pumps. Further, we have demonstrated that the nanoemulsion-based vaccines are not physically or chemically altered and retain potency following actuation with nasal spray devices. Using either device, the measured spray characteristics suggest deposition of nanoemulsion-based vaccines in inductive tissues located in the anterior region of the nasal cavity. CONCLUSIONS: The results of this study suggest that nanoemulsion-based vaccines do not require specially engineered delivery devices and support their potential use as nasopharyngeal vaccine adjuvants.


Subject(s)
Nanoparticles , Nebulizers and Vaporizers , Ovalbumin/administration & dosage , Vaccines/administration & dosage , Administration, Intranasal , Aerosols , Alkaline Phosphatase/administration & dosage , Alkaline Phosphatase/chemistry , Alkaline Phosphatase/immunology , Animals , Drug Stability , Drug Storage , Emulsions , Excipients/chemistry , Female , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Surface Antigens/chemistry , Hepatitis B Surface Antigens/immunology , Mice , Ovalbumin/chemistry , Ovalbumin/immunology , Particle Size , Sodium Chloride/chemistry , Swine , Vaccines/immunology
4.
PLoS One ; 3(8): e2954, 2008 Aug 13.
Article in English | MEDLINE | ID: mdl-18698426

ABSTRACT

BACKGROUND: Hepatitis B virus infection remains an important global health concern despite the availability of safe and effective prophylactic vaccines. Limitations to these vaccines include requirement for refrigeration and three immunizations thereby restricting use in the developing world. A new nasal hepatitis B vaccine composed of recombinant hepatitis B surface antigen (HBsAg) in a novel nanoemulsion (NE) adjuvant (HBsAg-NE) could be effective with fewer administrations. METHODOLOGY AND PRINCIPAL FINDINGS: Physical characterization indicated that HBsAg-NE consists of uniform lipid droplets (349+/-17 nm) associated with HBsAg through electrostatic and hydrophobic interactions. Immunogenicity of HBsAg-NE vaccine was evaluated in mice, rats and guinea pigs. Animals immunized intranasally developed robust and sustained systemic IgG, mucosal IgA and strong antigen-specific cellular immune responses. Serum IgG reached > or = 10(6) titers and was comparable to intramuscular vaccination with alum-adjuvanted vaccine (HBsAg-Alu). Normalization showed that HBsAg-NE vaccination correlates with a protective immunity equivalent or greater than 1000 IU/ml. Th1 polarized immune response was indicated by IFN-gamma and TNF-alpha cytokine production and elevated levels of IgG(2) subclass of HBsAg-specific antibodies. The vaccine retains full immunogenicity for a year at 4 degrees C, 6 months at 25 degrees C and 6 weeks at 40 degrees C. Comprehensive pre-clinical toxicology evaluation demonstrated that HBsAg-NE vaccine is safe and well tolerated in multiple animal models. CONCLUSIONS: Our results suggest that needle-free nasal immunization with HBsAg-NE could be a safe and effective hepatitis B vaccine, or provide an alternative booster administration for the parenteral hepatitis B vaccines. This vaccine induces a Th1 associated cellular immunity and also may provide therapeutic benefit to patients with chronic hepatitis B infection who lack cellular immune responses to adequately control viral replication. Long-term stability of this vaccine formulation at elevated temperatures suggests a direct advantage in the field, since potential excursions from cold chain maintenance could be tolerated without a loss in therapeutic efficacy.


Subject(s)
Emulsions , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Vaccines/administration & dosage , Adjuvants, Immunologic , Animals , Antibody Formation , Chemistry, Pharmaceutical , Dosage Forms , Hepatitis B Surface Antigens/immunology , Humans , Immunoglobulin G/blood , Mice , Particle Size , Recombinant Proteins/administration & dosage , Vaccines, DNA/immunology
5.
Nanomedicine ; 4(1): 57-69, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18249156

ABSTRACT

We describe the simple fabrication of poly({198Au}) radioactive gold-dendrimer composite nanodevices in distinct sizes (diameter between 10 nm and 29 nm) for targeted radiopharmaceutical dose delivery to tumors in vivo. Irradiation of aqueous solutions of 197Au containing poly(amidoamine) dendrimer tetrachloroaurate salts or {197Au0} gold-dendrimer nanocomposites in a nuclear reactor resulted in the formation of positively charged and soluble poly{198Au0} radioactive composite nanodevices (CNDs). A mouse melanoma tumor model was used to test whether the poly{198Au0} CNDs can deliver a therapeutic dose. A single intratumoral injection of poly{198Au0}(d=22nm) CNDs in phosphate-buffered saline delivering a dose of 74 muCi resulted after 8 days in a statistically significant 45% reduction in tumor volume, when compared with untreated groups and those injected with the "cold" nanodevice. No clinical toxicity was observed during the experiments. This study provides the first proof of principle that radioactive CNDs can deliver therapeutic doses to tumors.


Subject(s)
Brachytherapy/instrumentation , Gold Radioisotopes , Nanostructures , Cell Line, Tumor , Chromatography, High Pressure Liquid , Dendrimers , Electrophoresis, Polyacrylamide Gel , Humans , Magnetic Resonance Spectroscopy , Microscopy, Electron, Transmission , Polyamines , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
6.
Nanomedicine ; 3(4): 281-96, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17962085

ABSTRACT

There is growing interest in developing tissue-specific multifunctional drug delivery systems with the ability to diagnose or treat several diseases. One class of such agents, composite nanodevices (CNDs), is multifunctional nanomaterials with several potential medical uses, including cancer imaging and therapy. Nanosized metal-dendrimer CNDs consist of poly(amidoamine) dendrimers (in various sizes, surface substituents, and net charges) and inorganic nanoparticles, properties of both of which can be individually modified and optimized. In this study we examine effects of size and surface charge on the behavior of Au-dendrimer CNDs in mouse tumor models. Quantitative biodistribution and excretion analyses including 5-nm and 22-nm positive surface, 5-nm and 11-nm negative surface, and a 5-nm neutral surface CNDs were carried out in the B16 mouse melanoma tumor model system. Results seen with the 22-nm CND in the B16 melanoma model were corroborated in a prostate cancer mouse tumor model system. Quantitative in vivo studies confirm the importance of charge and show for the first time the importance of size in affecting CND biodistribution and excretion. Interestingly, CNDs of different size and/or surface charge had high levels of uptake ("selective targeting") to certain organs without specific targeting moieties placed on their surfaces. We conclude that size and charge greatly affect biodistribution of CNDs. These findings have significance for the design of all particle-based nanodevices for medical uses. The observed organ selectivity may make these nanodevices exciting for several targeted medical applications.


Subject(s)
Gold/chemistry , Gold/pharmacokinetics , Melanoma/metabolism , Nanoparticles/chemistry , Nanoparticles/ultrastructure , Prostatic Neoplasms/metabolism , Animals , Cell Line, Tumor , Male , Mice , Mice, Inbred C57BL , Mice, Nude , Organ Specificity , Particle Size , Tissue Distribution
7.
Dis Colon Rectum ; 50(8): 1230-40, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17587138

ABSTRACT

PURPOSE: Colon cancer is the third most prevalent cancer in the United States. However, the molecular mechanisms involved in the development and progression of colon cancer are incompletely understood. This study was initiated to explore the potential role of the receptor for advanced glycation end-products and S100P in modulation of key properties of human colon cancer cells. METHODS: Western blot, reverse transcription-polymerase chain reaction, and quantitative polymerase chain reaction were performed for detection of the receptor for advanced glycation end-products and S100P in colon cancer and matched normal colon. The influence of exogenously added S100P was analyzed on SW480 colon cancer cell line proliferation, migration, phosphorylation of mitogen activated protein kinases, and NFkappaB activation. To identify the mechanisms involved in these responses, coimmunoprecipitation examining the S100P/Receptor for advanced glycation end-products interaction and the effects of receptor for advanced glycation end-products inhibition in this interaction were analyzed. RESULTS: Although the receptor for advanced glycation end-products was present in normal and malignant colon specimens, only the malignant specimens expressed S100P. Treatment of SW480 cells with S100P increased proliferation and cell migration. Addition of exogenous S100P stimulated both ERK1/2 phosphorylation and NFkappaB activity. The interaction between S100P and the receptor for advanced glycation end-products was demonstrated by coimmunoprecipitation of these molecules from SW480 cells. Antagonism of the receptor for advanced glycation end-products blocked this interaction and the biologic effects of S100P on these cells. CONCLUSIONS: These data indicate that S100P is expressed at greater levels in colon cancer than matched normal tissue and that S100P stimulates colon cancer cell growth, migration, Erk phosphorylation, and NFkappaB activation in vitro, suggesting that this ligand/receptor pair may be targeted for the development of new therapies.


Subject(s)
Adenocarcinoma/pathology , Calcium-Binding Proteins/physiology , Colonic Neoplasms/pathology , Neoplasm Proteins/physiology , Receptors, Immunologic/physiology , Adenocarcinoma/metabolism , Cell Culture Techniques , Cell Line, Tumor , Cell Movement/physiology , Cell Proliferation , Colonic Neoplasms/metabolism , Humans , MAP Kinase Signaling System/physiology , Phosphorylation , Receptor for Advanced Glycation End Products
8.
Technol Cancer Res Treat ; 4(6): 603-13, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16292880

ABSTRACT

Our results indicate that the surface chemistry, composition, and 3-D structure of nanoparticles are critical in determining their in vivo biodistribution, and therefore the efficacy of nanodevice imaging and therapies. We demonstrate that gold/dendrimer nanocomposites in vivo, present biodistribution characteristics different from PAMAM dendrimers in a B16 mouse tumor model system. We review important chemical and biologic uses of these nanodevices and discuss the potential of nanocomposite devices to greatly improve cancer imaging and therapy, in particular radiation therapy. We also discuss major issues confronting the use of nanoparticles in the near future, with consideration of toxicity analysis and whether biodegradable devices are needed or even desirable.


Subject(s)
Dendrimers/pharmacokinetics , Melanoma, Experimental/metabolism , Nanostructures , Polyamines/pharmacokinetics , Animals , Dendrimers/chemical synthesis , Male , Mice , Mice, Inbred C57BL , Mice, Nude , Polyamines/chemical synthesis , Tissue Distribution
9.
Cancer Res ; 65(12): 5317-24, 2005 Jun 15.
Article in English | MEDLINE | ID: mdl-15958579

ABSTRACT

Prior studies suggested that nanoparticle drug delivery might improve the therapeutic response to anticancer drugs and allow the simultaneous monitoring of drug uptake by tumors. We employed modified PAMAM dendritic polymers <5 nm in diameter as carriers. Acetylated dendrimers were conjugated to folic acid as a targeting agent and then coupled to either methotrexate or tritium and either fluorescein or 6-carboxytetramethylrhodamine. These conjugates were injected i.v. into immunodeficient mice bearing human KB tumors that overexpress the folic acid receptor. In contrast to nontargeted polymer, folate-conjugated nanoparticles concentrated in the tumor and liver tissue over 4 days after administration. The tumor tissue localization of the folate-targeted polymer could be attenuated by prior i.v. injection of free folic acid. Confocal microscopy confirmed the internalization of the drug conjugates into the tumor cells. Targeting methotrexate increased its antitumor activity and markedly decreased its toxicity, allowing therapeutic responses not possible with a free drug.


Subject(s)
Antineoplastic Agents/administration & dosage , Drug Carriers/administration & dosage , Fluorescent Dyes/administration & dosage , Methotrexate/administration & dosage , Nanostructures , Polyamines/administration & dosage , Radiopharmaceuticals/administration & dosage , Animals , Antineoplastic Agents/pharmacokinetics , Carrier Proteins/metabolism , Dendrimers , Disease Models, Animal , Drug Carriers/pharmacokinetics , Female , Fluorescent Dyes/pharmacokinetics , Folate Receptors, GPI-Anchored , Humans , KB Cells , Methotrexate/pharmacokinetics , Mice , Mice, Nude , Mice, SCID , Polyamines/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Receptors, Cell Surface/metabolism , Tissue Distribution , Tritium/pharmacokinetics , Xenograft Model Antitumor Assays
10.
Pharm Res ; 21(3): 476-83, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15070099

ABSTRACT

PURPOSE: To determine the in vivo biodistribution for differently charged poly(amidoamine) (PAMAM) dendrimers in B16 melanoma and DU145 human prostate cancer mouse tumor model systems. METHODS: Neutral (NSD) and positive surface charged (PSD) generation 5 (d = 5 nm) PAMAM dendrimers were synthesized by using 3H-labeled acetic anhydride and tested in vivo. Dendrimer derivatives were injected intravenously, and their biodistribution was determined via liquid scintillation counting of tritium in tissue and excretory samples. Mice were also monitored for acute toxicity. RESULTS: Both PSD and NSD localized to major organs and tumor. Dendrimers cleared rapidly from blood, with deposition peaking at 1 h for most organs and stabilizing from 24 h to 7 days postinjection. Maximal excretion occurred via urine within 24 h postinjection. Neither dendrimer showed acute toxicity. CONCLUSIONS: Changes in the net surface charge of polycationic PAMAMs modify their biodistribution. PSD deposition into tissues is higher than NSD, although the biodistribution trend is similar. Highest levels were found in lungs, liver, and kidney, followed by those in tumor, heart, pancreas, and spleen, while lowest levels were found in brain. These nanoparticles could have future utility as systemic biomedical delivery devices.


Subject(s)
Dendrimers , Nanoparticles , Animals , Humans , Melanoma , Melanoma, Experimental , Tissue Distribution
11.
Arch Biochem Biophys ; 404(1): 71-9, 2002 Aug 01.
Article in English | MEDLINE | ID: mdl-12127071

ABSTRACT

Regulation of Glc7 type 1 protein phosphatase stability and activity was studied in budding yeast. We found that the Glc7 protein has a half-life of over 180min, which is sufficient for several generations. Glc7 protein stability was constant during the cell cycle and in batch culture growth. Furthermore, deletion of regulatory subunit Gac1, Reg1, Reg2, Sds22, or Glc8 had no influence on Glc7 protein half-life. The activity of Glc7 assayed as okadaic acid-resistant phosphorylase phosphatase activity was constant during the cell cycle. Deletion of the aforementioned regulatory subunits revealed that only Glc8 deletion had a significant effect in reducing Glc7 activity. Glc7 activity was induced during stationary phase in a Glc8-dependent manner. In addition, extracellular glucose repressed the induction of Glc7 activity. These results are consistent with glucose repression of Glc8 expression and favor the role of Glc8 as a major Glc7 activator.


Subject(s)
Enzyme Inhibitors , Fungal Proteins/metabolism , Phosphoprotein Phosphatases/metabolism , Saccharomyces cerevisiae Proteins/metabolism , Cell Cycle , Enzyme Activation , Enzyme Stability , Fungal Proteins/antagonists & inhibitors , Fungal Proteins/chemistry , Fungal Proteins/genetics , Gene Deletion , Genes, Fungal , Glucose/pharmacology , Mutation , Phosphoprotein Phosphatases/antagonists & inhibitors , Phosphoprotein Phosphatases/chemistry , Phosphoprotein Phosphatases/genetics , Plasmids/genetics , Protein Phosphatase 1 , Protein Subunits , Saccharomyces cerevisiae/drug effects , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Saccharomyces cerevisiae Proteins/antagonists & inhibitors , Saccharomyces cerevisiae Proteins/chemistry , Saccharomyces cerevisiae Proteins/genetics
12.
Yeast ; 19(2): 115-22, 2002 Jan 30.
Article in English | MEDLINE | ID: mdl-11788966

ABSTRACT

Combinations of two non-lethal mutations that result in cell death are synthetically lethal. Such a genetic relationship suggests a functional interaction between the corresponding gene products. Frequently, an ade2 ade3 colony-sectoring assay is used to screen for synthetic lethal mutants. In these screens, mutants are sought that fail to lose a plasmid that bears a gene of interest. However, a subset of mutants is often found that is dependent on plasmid components other than the target gene. To understand the mechanism of this dependence, we characterized those mutants that, although prevalent in most mutant hunts, are usually discarded. Using a LEU2-ADE3 plasmid, plasmid-dependent mutations were found in the SHM2, PTR3, BAP2 and SSY1 genes. Double shm2 ade3 mutants are non-viable because the two pathways for tetrahydrofolate synthesis are blocked. Mutations in PTR3, BAP2 and SSY1 disrupt sensing and transport of extracellular leucine. Therefore, ptr3, bap2 or ssy1 mutants must be leucine prototrophs to grow on rich media. In light of these findings, we propose modifications that should improve the efficiency of synthetic lethal screening procedures.


Subject(s)
Alcohol Oxidoreductases/genetics , Aminohydrolases/genetics , Formate-Tetrahydrofolate Ligase/genetics , Genes, Fungal , Genes, Lethal , Methylenetetrahydrofolate Dehydrogenase (NADP)/genetics , Multienzyme Complexes/genetics , Saccharomyces cerevisiae/genetics , 3-Isopropylmalate Dehydrogenase , Genetic Techniques , Mutation , Plasmids , Saccharomyces cerevisiae/enzymology
SELECTION OF CITATIONS
SEARCH DETAIL
...